Menu
Advanced
Structure search
List search
EN
CN
ES
FR
JP
KR
Wish Lists
Cart
Sign in
Sign in
Contact us
Catalog
of Screening Compounds
Screening Libraries
Building Blocks
Advanced
Structure search
List search
Homepage
>
Company
>
Media
>
Pharma News
>
2024
>
Qureight secures Series A funding to accelerate drug development
Qureight secures Series A funding to accelerate drug development
Read also
Scientists reveal new method that could reduce waste from drug manufacturing
The new method could help to prevent severe side effects caused by enantiomer drugs.
FDA Grants Fast Track Designation to CTX-009 Plus Paclitaxel for Pretreated Biliary Tract Cancer
CTX-009 plus paclitaxel has received FDA fast track designation for pretreated metastatic or locally advanced biliary tract cancer.
Pfizer scores FDA nod for hemophilia B gene therapy, will charge $3.5M per dose
Pfizer will offer a warranty program for its first FDA-approved gene therapy.
Long flu season winds down in US
The U.S. flu season appears to be over. It was long, but it wasn't unusually severe.
0
item
s
in Cart
Cart Subtotal:
Go to cart
You will be able to Pay Online or Request a Quote
Catalog
Services
Company
Catalog of Screening Compounds
Screening Libraries
Focused and Target Libraries
Active Reference Sets
Diversity Libraries
Preplated libraries
Screening Compounds
Building blocks
Drug Discovery Services
Custom chemistry. Chemistry FTE. Resynthesis.
Medicinal chemistry FTE
In silico drug design (CADD)
Discovery Biology. Biology FTE. In vitro studies.
Animal models
Toxicology and safety
ADME, DMPK. In vivo studies
Chemistry, manufacturing and controls
Company
News & Media
Contact us
For suppliers
Trends in discovery compounds